Further, Boscia et al. [41] found that in patients with nvAMD, those with diabetes had a significantly lower reduction in the macular neovascularization (MNV) area during anti-VEGF treatment, as assessed by OCT angiography (OCTA). This evidence concerns the gene VEGFA and diabetes mellitus.